Tau-dependent LMTM treatment effects that are subject to interference by prior treatment with AD-approved drugs include reversal of behavioral deficits, effects on synaptic SNARE-complex proteins, and increase in brain mitochondrial Complex IV activity. Here, MAPT is linked to Alzheimer disease.